血清CEA、CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响

目的 探讨晚期非小细胞肺癌（NSCLC） 患者血清癌胚抗原（CEA） 、糖类抗原（CA125）、非小细胞肺癌相关抗原（Cyfra21-1）水平与无疾病进展生存期的相关性。方法 选取2012年6月至2014年5月于宜昌市第二人民医院确诊的非小细胞肺癌患者120例，对其临床资料进行回顾性分析，了解CEA、CA125、Cyfra21-1水平与无疾病进展生存期的相关性。结果 与鳞癌患者相比，血清CEA水平在肺腺癌患者中明显升高（P＜0.05）；血清CA125水平在Ⅳ期肺腺癌患者中明显升高（P＜0.05）；血清Cyfra21-1在患者疾病一般特征中差异未见统计学意义（P＞0.05）。血清CEA、CA125、Cyfra21-1水平升高的患者中位无疾病进展生存期分别为4.2、4.5、4.3月，与正常组相比差异均有统计学意义（P＜0.05）。结论 晚期非小细胞肺癌患者CEA、CA125、Cyfra21-1升高与无疾病进展生存期存在明显的相关性，临床医师可通过检测患者血清CEA、CA125、Cyfra21-1水平判断预后。

Prognostic Value of Serum CEA,CA125 and Cyfra21-1 in Patients with Advanced Nonsmall Cell Lung Cancer

Objective To analyze the prognostic value of tumor markers CEA, CA125 and Cyfra21-1 in advanced non-small cell lung cancer(NSCLC) patients. Methods We retrospectively reviewed the clinical data of 120 NSCLC patients diagnosed in the Second Hospital of Yichang from June 2012 to May 2014, to observe the relationship between CEA, CA125, Cyfra21-1 levels and progression-free survival(PFS). Results Compared with squamous cell carcinoma, serum CEA levels in patients with adenocarcinoma was significantly increased (P<0.05); serum CA125 levels were significantly elevated in stageⅣadenocarcinoma patients(P<0.05); serum Cyfra 21-1 had no significant differences in general characteristics of patients (P>0.05). The PFS in patients with high levels of CEA, CA125 and Cyfra21-1 were 4.2, 4.5 and 4.3 months, with significant difference compared with healthy controls(P＜0.05). Conclusion The rise of CEA, CA125, Cyfra21-1 expression are significantly correlated with the progression-free survival of advanced NSCLC patients, and the clinicians can judge the prognosis by detecting the serum CEA, CA125, Cyfra 21-1 levels in patients.